A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every 3 Week Brentuximab Vedotin
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab
- Indications Lymphoma
- Focus Therapeutic Use
- 02 Nov 2017 New drug Nivolumab has been added in the study. Hence treatment arms has been changed from 1 to 2.
- 02 Nov 2017 Planned number of patients changed from 20 to 40.
- 02 Nov 2017 Status changed from active, no longer recruiting to recruiting.